Matchpoint Therapeutics

Acing the future of covalent medicines

[Matchpoint Therapeutics @matchpointtx]

We’re thrilled to be working with @Novartis to develop oral covalent inhibitors directed at a transcription factor, and historically hard-to-drug protein, linked to a number of inflammatory diseases. https://t.co/IsjNeogpEw

[Matchpoint Therapeutics @matchpointtx]

Wishing everyone a wonderful holiday season from the team at Matchpoint!

[Matchpoint Therapeutics @matchpointtx]

Wishing everyone a Happy Thanksgiving from the team at Matchpoint - which we’re very thankful for!

[Matchpoint Therapeutics @matchpointtx]

Matchpoint brings together passionate drug hunters, technical experts, and seasoned company builders - unified by our values and the goal of developing precision covalent medicines that transform the lives of those impacted by serious disease. https://t.co/W5USH4giEf

[Matchpoint Therapeutics @matchpointtx]

Edward Chouchani comments on how our ACE platform can overcome the challenges that previously limited the development of precision covalent medicines. https://t.co/OFVA2YOa91

[Matchpoint Therapeutics @matchpointtx]

The resurgence of covalent medicines ~15 years ago led to important medicines. With our Series A, we are building on this legacy by deploying the power of covalency to the field of immunology. Chairman of our BOD, Bruce Booth, comments. https://t.co/OFVA2YOa91 @LifeSciVC

[Matchpoint Therapeutics @matchpointtx]

Our Co-founder Nathanael Gray shares his thoughts on where our platform can go, and how it has the potential to screen for highly selective medicines early in the discovery process. https://t.co/OFVA2Yx771

[Matchpoint Therapeutics @matchpointtx]

At Matchpoint we’re exclusively developing covalent medicines and have set our sights on transforming the treatment of serious immune diseases. https://t.co/OFVA2YOa91

[Matchpoint Therapeutics @matchpointtx]

Today we announced the launch of Matchpoint Therapeutics - founded to harness the power of covalency to develop precision small molecule medicines for immune diseases. Check out the press release here. https://t.co/OFVA2YOa91